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DEFINITIONS/TERMS.  
Healthcare Associated Infection: Infections that occur as a result of contact with healthcare 
facilities.  The infections are not present or incubating at the time of admission. In general they do not 
manifest within the first 48 hours after contact with the healthcare facility, and include infections 
acquired whilst within a healthcare facility but manifesting after discharge.  Occupational related 
infection of health care workers and iatrogenic infections are also classified as HAI.  
Healthcare Facility: Includes any facility in which patients are managed as well as healthy 
individuals that attend to obtain preventative health care. This includes hospitals, community health 
centres, primary healthcare clinics and emergency medical service facilities.  
Key Priority Area: Based on the major concerns expressed by patients through surveys, complaints 
and media reports, six priority areas have been identified to fast-track improvement in provision of 
health care in South Africa.   
Non-Fastidious Microbes: Species of microbes that are able to grow without special nutritional 
supplements or environmental conditions.   
Pulsed Field Gel Electrophoresis: Methodology to separate of large deoxyribonucleic 
acid  fragments by applying to a gel matrix an electric field that periodically changes direction.   
Total Parenteral Nutrition: Administering fluid that contains nutrients intravenously.   
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PREFACE 
Infection Prevention and Control is a key priority area in South Africa.  Primarily, the focus is 
preventing healthcare associated infections. The importance of infection prevention is not just related 
to patient safety but it is a critical element of antimicrobial stewardship. In order to significantly 
reduce healthcare associated infection, it is critical to understand the mechanisms that cause these 
infections before implementation of measures to mitigate these risks. Monitoring compliance to policy 
is a key element of ensuring the desired outcome of any policy. 
There are various modes of transmission which include contact, droplet, airborne, common vehicle 
and vector transmission. Globally and also in South Africa, there have been reports of outbreaks 
related to the use of medication vials.  Klebsiella pneumoniae, Hepatitis C and even Plasmodium 
falciparum has been implicated in such outbreaks. In the most devastating outbreak reported in 
KwaZulu-Natal (KZN), 22 of 26 babies in a neonatal intensive care unit demised. The source was 
confirmed to be a vial of single use Vamin-Glucose that was used for multi-dosing. It has been 
postulated the multiple use of medication vials present a significant risk to the patient. The one vial, 
one patient advocacy presents the safest option. However, in a resource limited setting such as in 
KZN, cost and drug shortages are key drivers which play an important role to decide on whether or 
not to maintain the one vial, one patient practice. Given the circumstances faced by most healthcare 
facilities, it is important to determine the level of risk that different medications present by 
determining whether or not these can be a reservoir of a pathogen. K. pneumoniae is a species with 
low nutritional requirements and a fast multiplication rate and is often associated with healthcare 
associated infections and outbreaks.  
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ABSTRACT 
Background and objectives: Klebsiella pneumoniae is frequently implicated in healthcare associated 
infections. This organism is non–fastidious and easily transmitted in a healthcare environment. 
Medication fluids are an ideal vehicle for transmission of these organisms. This study aimed to 
determine if K. pneumoniae would proliferate in various medication fluids.  
Method: The behaviour of K. pneumoniae was studied in piperacillin/tazobactam, ciprofloxacin, 
meropenem, insulin, heparin, lignocaine, and gentamicin, concentrations (50-2 %) of dextrose, 
Neonatalyte® and saline. This was assessed over a 24-hour period at 25 
o
C and 35 
o
C. 
Results:  K. pneumoniae did not proliferate in the antibiotics or the multi-dose vials. The bacteria 
persisted in Neonatalyte® and saline. Bactericidal activity was observed in 50 %, 25 % and 12.5 % 
dextrose at both incubation temperatures. In 10 %, at 24 hours post inoculation, a decrease of 57 % 
and 50 % was observed at 25 
o
C and 35 
o
C respectively. At concentrations of 6 %, 3 % and 2 %,   
after 24 hours post inoculation at 25 
o
C, the colony count increased by 112 %, 124 % and 133 % and 
at 35 
o
C by 120 %, 134 % and 150 % respectively. There was no difference in the behaviour of K. 
pneumoniae at 25 
o
C and 35 
o
C. Neonatalyte® and saline demonstrated no increase in the cfu/mL over 
24 hours.   
Conclusions: Persistence of the test bacteria in saline, neonatalyte and lower concentrations of 
dextrose has been shown. This poses serious risk to patient care if the bacteria inadvertently enter the 
fluid due to infection prevention breeches. 
 
 
 
 
 
 
 
 
 
1 
 
CHAPTER: ONE 
 
INTRODUCTION 
Multiple-dose vials are liquid medication containing vials that are intended for multiple dose 
medication via parenteral administration. This can be by intravenous or intramuscular injection or by 
infusion. (1) These vials are labelled as multi-dose vials by the manufacturer and contain an 
antimicrobial preservative which inhibits bacterial growth. (2) The preservative is not effective 
against viruses, protozoan, parasites or prions. (2) Strictly, only these vials, that contain a preservative 
and are labelled by the manufacturer as multiple-dose vials, should be used as such. 
Multiple-dose vials are intended to provide a convenient and cost effective therapeutic option. In a 
resource limited setting; the latter can play an important role in decision making. (3) Multiple-dose 
vials allow multiple aspirations. There is no wastage per dose. In any establishment, financial costs 
play a role in decision making but in a healthcare facility, risk to safe patient care must weigh heavily 
in this decision making process. In an unregulated setting, use of these vials can be detrimental to 
patient safety. (2)  
Recommendations from the Centers for Disease Control and Prevention state that, “Multiple-dose 
vials should be dedicated to a single patient whenever possible. If multiple-dose vials must be used for 
more than one patient, it should only be kept and accessed in a dedicated medication preparation area 
(e.g., medication room), away from immediate patient treatment areas. This is to prevent inadvertent 
contamination of the vial through direct or indirect contact with potentially contaminated surfaces or 
equipment that could then lead to infections in subsequent patients. If a multiple-dose vial enters an 
immediate patient treatment area, it should be dedicated for single-patient use only.” (1) The name of 
the patient should be on the vial as well as the date and time of first use. 
The World Health Organisation (WHO) provides guidance on the safe use of multiple-dose vials. (4) 
Whilst these recommendations are applicable to vaccines, the scientific rationale applied by WHO are 
also relevant to other multiple-dose vials. In order to ensure the safety and efficacy of the vial, there 
are various factors that must be taken into consideration. These include assessing the preservative to 
determine effectiveness in preventing bacterial contamination and also stability of the medication over 
various temperatures and times. WHO further advises that, if the medication does not contain 
preservatives or if there is insufficient evidence that the preservative is effective in preventing 
bacterial contamination, a time limit of six hours or one immunization round should be applied for use 
of the vial.  (4)  
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Thiomersal is a preservative used in DTaP and one DTaP-Hib combination vaccine. (5) It is a 
compound that contains mercury, which is found naturally in the environment. (5, 6) In 1999, Food 
and Drug Administration (FDA) conducted a review of the use of thiomersal in childhood vaccines 
and found no evidence of harm from its use as a vaccine preservative, other than a reaction at the 
injection site. In 2001, the Institute of Medicine’s Immunization Safety Review Committee reached a 
similar conclusion, based on a review of available data, and again in 2004, after reviewing studies 
performed after its 2001 report. (6) 
 
The National Department of Health: South Africa provides guidance on the use of multiple-dose vials. 
This, however, pertains largely to vaccines and is aligned with the WHO recommendations. (7) 
The South African Society of Anaesthesiologists (SASA) Guidelines for Infection Control in 
Anaesthesia in South Africa, 2014, gives vague guidance on the safe use of multiple-dose vials. This 
document fails to give a precise definition of multiple-vials, exact disinfection procedure, importance 
of adherence to manufacturer’s instructions, criteria for use on multiple patients, disposal of the vial 
or storage limitations once opened. (8) A significant number of medications used in anaesthesia are 
intended for multiple dosing. (9, 10) In a surveillance of anaesthesia medication by Heever et al 
(2012), a microbial contamination was found in 6 % was found. (9)  
 
The Department of Health: KwaZulu-Natal (KZN), has formulated a policy entitled: “Correct use of 
single-dose and multiple-dose injections and large parenteral and total parenteral nutrition solutions in 
order to prevent contamination”, (2005). (10) This policy allows multiple-dose vials to be used for 
multiple withdrawals provided that infection prevention measures are adhered to, the vial has not been 
submerged in water, the date of opening is indicated, room air is not injected into the vial and that the 
storage time once opened is 30 days or as per manufacturers’ recommendation. (10) Vials used in this 
way must be discarded thereafter. (10) The policy however recommends storage at 4 
o
C.  (10) 
Preservatives exert their action on organisms that are actively metabolising. At lower temperatures, 
metabolism of most bacteria is reduced. Refrigeration of medications at lower temperatures when not 
indicated by the manufacturer can have an opposite effect as the bacteria may then be protected from 
the action of the preservative. When injected into the patient, the preservative is then diluted and the 
bacteria enter a nutrient rich environment which allows active bacterial proliferation. (11, 12)  
 
The Department of Health KZN: Infection Prevention and Control Guidelines, Chapter 24: In 
neonatal intensive care units it is recommended that the vial should be labelled with date and time of 
opening and stored in accordance with the manufacturers’ recommendation. (13) The vial may be 
used for multiple patients within the same medication round. (13) The medication round should not 
exceed twenty minutes. (13)The KZN Infection Prevention and Control Guideline recommends 
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cleaning of the vial with 0.5 % chlorhexidine in 70 % alcohol solution and allowing the rubber septum 
to dry before use. (13)  Single use of needles and syringes is also recommended. (13) 
Whilst guidelines are in place to guide the safe use of multi-dose vials, factors such as infrastructure, 
staffing and overcrowding contribute to behavioral changes that have negative impact on infection 
prevention practices. (14) Furthermore financial costs (15) and drug shortages often dictate a more 
cost centered approach to the use of medication fluids. In the absence of evidence based regulations 
and monitoring of the use of medication vials, the consequence is possibly detrimental to patient care 
and subsequent medical costs 
Klebsiella pneumoniae is a gram negative bacterium (16) which is frequently implicated in healthcare 
associated infections (HAI) and hospital outbreaks (17–19) The bacterium is spread via contact 
transmission. (16) K. pneumoniae is part of the commensal flora of the intestinal tract. (16)  The 
organism is non-fastidious and easily transmissible in a healthcare environment. (16) Patients 
admitted to high risk areas in a healthcare facility such as Intensive Care Units and Neonatal Units are 
vulnerable to acquiring infections due to the invasive nature of procedures in these units and 
indwelling devices. (16) The use of parenteral medication is seen as a major contributing risk factor to 
HAIs. 
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CHAPTER TWO 
 
BACKGROUND 
In 2005, 22 out of 26 (86 %) babies demised during one of the most devastating outbreaks in 
KwaZulu-Natal (KZN).  The outbreak occurred in Mahatma Gandhi Memorial Hospital. Klebsiella 
pneumoniae was isolated from the blood cultures of 25 babies. One baby had Klebsiella oxytoca in the 
blood culture. Various environmental sites, formula feeds, expressed breast milk, medication and 
intravenous fluids were all tested for K. pneumoniae. All were found to have no growth besides four 
bottles of Vamin-Glucose. The unopened bottles were also tested and found to be sterile. The Vamin-
Glucose was for single use but in this case it was used as multiple-dose medication. (20) Two years 
after this outbreak, K. pneumoniae was once again implicated in an outbreak at Prince Mshiyeni 
Regional Hospital. Five out of seven (71 %) babies demised. Re-use of intravenous fluids and 
medications were once again implicated. (21)(22) After this outbreak, multiple dosing was 
discontinued. (23) The KZN: Department of Infection Prevention and Control adopted the Centre for 
Disease Control’s “One and Only Campaign” approach.  This stipulated the use of one needle, one 
syringe and one medication vial per patient, even for multiple-dose vials. (24) Whilst this may have 
been the safest option, the one vial per patient approach was not sustainable. Thus, it became 
necessary to study the proliferation of K.  pneumoniae in the medication fluids and the parameters that 
could contribute to contamination of medication fluids commonly used in a Regional Hospital in 
KZN.  
Parenteral administration of medication forms one of the cornerstones of clinical care. (25)  Several 
medications are available in multiple-dose vials.  Reasons for medications being presented as 
multiple-doses per unit include convenience to the user and cost effectiveness. Those vials labelled as 
multiple-dose vials by the manufacturer are designed for multiple use. These vials contain a 
preservative to inhibit bacterial growth (25) this does not protect the fluid from  fungal or viral 
contamination. (26)  Multiple-dose vials are subjected to many withdrawals under the assumption that 
the vials are sterile and resistant to contamination. The rubber stoppers of such vials have a self-
sealing capacity and are able to withstand multiple withdrawals.  Self-sealing capacity refers to the 
ability of the rubber stopper to prevent microbial entry into the vial and prevent product loss during 
and between uses. (27)  
Single dose medications are intended to be used for a single injection on a single patient. These 
medications are usually labelled as single dose vials and lack any antibacterial agents that could 
prevent bacterial growth.  Some single dose vials may appear to contain multiple doses due to the 
volume they contain. In these instances, healthcare professionals are often tempted to use these for 
multiple dosing to avoid wastage. Such decisions have compromised patient safety and consequently 
escalated hospital costs. 
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2.1 Outbreaks 
2.1.1 Insulin identified as source of outbreak 
Contaminated medication fluids have been implicated in outbreaks. (15, 20, 28–35) Some were 
confirmed microbiologically but most were hypothesized after epidemiological investigations. In 
2001, in an intensive care unit in Malaysia, 12 patients had blood stream infections with Serratia 
marcescens. (36)  Environmental sampling revealed insulin and a sedative solution to be the source. 
The strain relatedness was confirmed using pulsed field gel electrophoresis (PFGE). The authors did 
not mention if the vial was used as per manufacturer’s recommendation.  (36) In a publication from 
Italy in 2006, another outbreak with S. marcescens was reported in a surgical ward in a community 
hospital. (37) Six patients had positive blood cultures with this organism. Five patients received total 
parenteral nutrition (TPN) but all six received intravenous insulin.  Insulin was diluted with 10 mL of 
poligeline. This was then added to the TPN solution in order to decrease adhesion of insulin to the 
bag. The poligeline was from a 500 mL bottle which was meant for single-use but was used for more 
than one patient and stored at room temperature for three to seven days. S. marcescens was cultured 
from the in-use TPN solutions. The in-use insulin and poligeline was not cultured as the vials were 
discarded.  The authors concluded that the most probable sources was the TPN solution which insulin 
was added with/or poligeline solution. (38) 
2.1.2 Heparin identified as source of outbreak 
2.1.2.1 Heparinised saline syringe contamination at manufacture plant 
In a multistate outbreak in the Unites States of America, Pseudomonas fluorescens was isolated from 
various specimens including blood obtained from indwelling central venous catheters and peripheral 
veins; sections of explanted catheter and from a catheter wound site. (31) Eighty patients were 
involved. This outbreak lasted from December 2004 to March 2006. Common to all of these patients 
was the use of heparinised saline intravenous flushes. The syringes were prepared at a compounding 
pharmacy. A compounding pharmacy is a pharmacy where medications are altered or mixed to create 
customised medications. Nine lots of prepared syringes were tested. Seven were found to be positive 
for P. fluorescens. The isolates from the syringes and the fifty-nine patients were then subjected to 
PFGE. The isolates were found to be genetically related. The exact constituent of the syringes and the 
manner in which the heparin was used and stored was not mentioned. (31) In another multistate 
outbreak, this time with 162 cases over nine states in the Unites States of America, S.  marcescens 
was involved. (39) The outbreak occurred from November 2007 to January 2008. A major risk factor 
identified was that all patients received heparin flushes from a particular lot of prefilled syringes. The 
heparin from the unopened syringes was cultured and grew S. marcescens. These isolates were found 
to be genetically related to the patients’ isolates.  (39) More recently, in 2018, heparin saline syringes 
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were once again responsible for an outbreak of S. marcescens involving 14 children. The children 
received intravenous medication via a catheter or central line. S. marcescens was not isolated form the 
unopened syringes but all syringes were recalled out of caution. (40) 
2.1.2.2. Heparin catheter lock solution contamination 
Central venous catheters are used for prolonged periods of time. They are used for administration of 
medication, blood products, TPN, for haemodialysis and to monitor the haemodynamic status of 
patients. In 2003, in San Paulo, Brazil, 32 cases of Pseudomonas putida and nine cases of 
Stenotrophomonas maltophilia were reported. (41) Five of the 32 cases of P. putida with were mixed 
with S. maltophilia.  All patients had central venous catheters. The catheters were infused with a 
heparin catheter lock solution. P. putida was isolated from the prefilled syringes. S maltophilia was 
not cultured from the syringes but the strains showed relatedness to each other. Genotyping confirmed 
a link between the P. putida from the patients and those from the syringes. The authors highlighted 
the risk associated with the use of intravenous fluids prepared by a compounding pharmacy. (41) 
2.1.2.3 Multiple-dose vial of heparin identified as source of outbreak 
In 2008, in Hospital de Clinicas in San Paulo, Brazil, 24 bacteraemia cases were investigated as part 
of a possible outbreak. (33) The organisms involved belonged to the Bukholderia cepacia complex. 
Twenty-three isolates from 21 patients could be retrieved for genotyping. One isolate did not belong 
to the B. cepacia complex. The remainder isolates were found to be polyclonal with B. multivorans as 
the predominant type.  Two different isolates from two patients were typed and these were not 
genetically related.  The patients with the predominant type had their central venous catheters flushed 
with saline and heparin. The multiple-dose vials were not available for culturing. The link between the 
multiple-dose vials and the bacteraemias was hypothesised after the interrogation of patient details 
and an audit of infection prevention measures. It was found that there were many breaches in 
compliance with infection prevention protocols. This included poor hand hygiene practices, poor 
environmental hygiene, poor handling of medication vials and medication fridges were not 
temperature monitored. Laminar flow cabinets used to store pre-prepared syringes until administration 
were poorly maintained. Authors hypothesised that the laminar flow cabinet was also a probable 
source but cultures were negative. This negative culture was attributed to not dismantling the laminar 
flow properly for swabbing.  Following re-enforcement of good infection prevention measures and 
proper maintenance of the laminar flow cabinet including cleaning and disinfection, the outbreak was 
halted. (33) 
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2.1.3. Lidocaine identified as source of outbreak 
In August 2001, in Tennessee, United States of America, five patients were investigated for septic 
arthritis or soft tissue infection. (12) Staphylococcus aureus was isolated. (12) Pulsed Field Gel 
Electrophoresis (PFGE) was done on these isolates. Four were found to be related. Common amongst 
these patients was that they received lidocaine injections between August 13
th
 and August 17
th
.   
Unopened vials were tested and found to have no growth. It was reported that the in-use vial of 
lidocaine was stored at 4 
o
C but the vial was not available for testing. Although the lidocaine had a 
preservative, the preservative could only exert its action on actively metabolising organisms. In the 
refrigerator, most organisms slow down their metabolism or do not metabolise at all. Thus 
refrigeration of the vials actually protected the organisms from the action of the preservative which 
later caused an infection when injected into the patient. (11, 12) Since all patients had received 
lidocaine injections from the same vial, it was hypothesised that this was the source.  (12) 
2.1.4. Multi-dosing from single-use dextrose identified as source of outbreak 
In 1996, in a neonatal intensive care unit in Puerto Rico, six patients were diagnosed with blood 
stream infection. Enterobacter cloacae and Pseudomonas aeruginosa were isolated from five patients 
and one had E. cloacae only. (42) The E. cloacae isolates belonged to one clone and so did the P. 
aeruginosa isolates.   An audit of the infection prevention practice revealed non-compliance with 
many protocols.  Apart from poor hand hygiene it was found that the medication room was cluttered 
with used utensils and equipment, prepared syringes were found amidst pools of stagnant water, and 
rubber septa of medication vials were disinfected with povidone-iodine but not allowed to dry before 
use. Intravenous fluids and electrolyte solutions were prepared by the staff in the neonatal intensive 
care unit. The intravenous solution was known as Mezclas and consisted of calcium gluconate, 
potassium chloride, saline and 5-20 % dextrose.  The dextrose was added to the solution from a 50 
mL vial that was used until empty. Environmental sampling was done. The cultures from the swabs 
taken from the hand wash facility grew E. cloacae and P. aeruginosa. These were unrelated to the 
outbreak strains. The dextrose could not be microbiologically confirmed, as the source of the outbreak 
as the in-use vial of dextrose was discarded. Authors concluded that the E. cloacae and P. aeruginosa 
had been brought in by a patient and transferred onto the hands of the healthcare workers. Subsequent 
non-compliance to hand hygiene and disinfection of the rubber septum contaminated the rubber 
septum. The organisms were then inadvertently introduced into the fluid during withdrawal of the 
fluid. (42)  
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2.1.5. Multiple-dosing of single-use Vamin-Glucose identified as source of outbreak 
In 1996, an outbreak occurred in a provincial hospital in Gauteng. There was an outbreak of 
necrotising entercolitis and nine babies demised. The causative organism was E. cloacae, which was 
isolated from three blood cultures. The unit was short staffed and poor hand hygiene was observed. 
Vamin-Glucose was added to saline or neolyte. Although meant for single dosing, the Vamin-Glucose 
was multiple dosed and visibly turbid. Environmental sampling was done.  The outbreak strain of E. 
cloacae was isolated from the hands of the healthcare workers, nebuliser water, neolyte, saline and the 
Vamin-Glucose. The authors concluded that the Vamin-Glucose was the source and highlighted the 
importance of maintaining basic infection prevention measures. (34) 
2.2 Contamination of in-use medication 
In Wisconsin, United States of America, Sheth, et al  tested 197 in-use medication vials. (43) Prior to 
testing, there had been between one and ten withdrawals from each vial. All vials were tested for 
bacterial and fungal contamination. There was no growth after seven days of incubation. (43) In 
another study, in Namazi Hospital, Shiraz, Iran, in 2006, six hundred and thirty six in-use medication 
vials were collected from thirty six wards. The medications were mainly potassium chloride, saline, 
sodium bicarbonate, calcium carbonate, insulin, and distilled water. None of the vials were used 
beyond expiry date but all were used for multiple patients and all were stored at room temperature. 
The bacterial contamination was detected in 5.6 % of these vials. The most frequently isolated 
organism was S. epidermidis. The only vial of insulin tested was from the emergency unit and this 
contained beta haemolytic streptococci. S. epidermidis and Streptococcus viridans were isolated from 
the saline. (30) Insulin was found to be the most frequently contaminated fluid in a study by Baniasadi 
et al (2013). Two hundred and five vials were tested. Eleven were contaminated. Three vials of 
insulin were positive either with Candida species, Micrococcus species or Escherichia coli. These 
vials were stored between 4-6 
o
C. (44) This study highlighted the impact on insulin as a result of non-
adherence to manufacturers’ recommendations on storage temperature.  
Longfield et al tested 1223 vials including insulin, heparin and xylocaine. None of the vials were 
contaminated. (32) In two separate studies, in-use vials with heparin were tested for bacterial 
contamination. Mattner et al tested 41 vials of heparin which represented 18 % of the total vials 
tested.  (29) Baniasadi et al tested 11 vials of heparin which represented 5 % of the total vials tested. 
(44) Both the studies did not find any bacterial growth from these vials.  
Rathod et al aimed to assess the sterility and stability of insulin used in the community. (45) Sixty 
nine vials from 50 patients who used insulin at home were tested. The average duration of use was 55 
days, which exceeded the recommended 28 days. All patients used disposable syringes but nine 
admitted to re-using these between two and fourteen times.  Eight of the vials grew 1 cfu/mL of either 
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S.  epidermidis or Propionibacterium acnes. One patient was found to have an injection site abscess 
with K. oxytoca. This study concluded that even when insulin was used for beyond 30 days; it did not 
get contaminated with pathogens. (45) 
Khalili et al, collected in-use multiple-dose vials, single dose vials and admixtures. (46) These were 
then tested for bacterial contamination.  Included in this collection were three multiple-dose vials, 40 
single dose vial and 109 admixtures.  The admixtures were prepared either in the treatment room or a 
clean room.  Ninety two admixtures were prepared in the treatment room and 17 were prepared in the 
clean room. The clean room was defined as an area which was used solely for preparation of 
medication. The room was equipped with a laminar flow cabinet, air filter and users were required to 
wear specialised clothing. (46) Of the 40 single dose vials, four vials were 50 % dextrose. Of the 108 
admixtures, there were 45 admixtures with 5 % dextrose, seven admixtures with 10 % dextrose, eight 
admixtures with 5 % dextrose and 0.9 % saline and three admixtures with 0.33 % dextrose with 0.3 % 
saline. Only one of the total of 92 admixtures prepared in the treatment room (1 L NaCl 0.45 % plus 
10 mL KCl 15 % and 2.5 mL MgSO4) was contaminated with Bacillus subtilis. (46) Authors 
concluded that although the multiple-dose vials did not yield any growth, the manner in which 
admixtures were prepared was a major risk. The importance of hand hygiene, injection safety, and 
environmental hygiene, preparation of medication in a clean room and correct handling of medication 
vials were listed as critical to prevent bacterial contamination of intravenous fluids. (46) 
In 2001, a study was carried out in Hanover, Germany to determine the risk associated with the use of 
multiple-dose vials. (29) All opened vials were collected from the wards. The vials were tested for 
bacterial contamination and checked for storage conditions and compliance to manufacturers’ 
instructions.  Two hundred and twenty-seven vials were collected. One hundred and thirteen of the 
vials were undated. Of the one hundred and fourteen dated vials, fifteen had passed the expiration date 
by up to fourteen days.  S. epidermidis was isolated from saline and from a spike device on another 
saline bottle. The bacterial contamination rate was found to be 0.9 %. It was concluded that 
preservative free solutions such as saline could possibly lead to severe infections and that although S. 
epidermidis was isolated, it was conceivable that any organism can contaminate these fluids. Vial 
spike devices that contained filters to prevent bacterial contamination were used.  However, this study 
showed that even these devices were prone to contamination. The authors felt that use of these filter 
containing devices could lead to a false sense of safety and thus encourage improper handling of vials. 
They recommended hand hygiene and proper handling of medication fluids but the most important 
recommendation was to avoid multiple uses of preservative free solutions.  (29)  
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2.3 In vitro studies 
Highsmith, et al experimented with various multiple-dose vials in order to assess if the medication 
fluids were either bactericidal, allowed persistence or proliferation of bacteria. (47) Amongst the 
medication fluids tested were insulin, heparin and lignocaine.  Insulin was tested at 4 
o
C and 25 
o
C. 
Thirteen micro-organisms were included in this panel: Acinetobacter calcoaceticus, Enterococcus, 
Enterobacter agglomerans, E. cloacae, Escherichia coli, K. pneumoniae, Proteus mirabilis, P. 
aeruginosa, Pseudomonas cepacia, S. marcescens, S. aureus, S. epidermidis, and Candida albicans.  
A single colony of each organism was picked up and inoculated into brain heart infusion broth. The 
broth was then incubated for 18 hours at 35 + 1 
o
C. The cells were washed three times using 0.25 % 
peptone water in saline.  Cells were then resuspended in 0.25 % peptone water in saline.  The 
resuspended cells were the diluted to achieve an inoculum density of 300 cfu/mL and then inoculated 
into 30 mL of the medication fluid to yield a concentration of 10 cfu/mL. The experiment was 
repeated using 0.9 % saline to wash, resuspend and dilute.   The experiment was carried out up to 168 
hours. With insulin, when the inoculum was prepared with 0.25 % peptone water in saline or 0.9 % 
saline, K. pneumoniae did not survive at either of the incubation temperatures. C. albicans survived at 
168 hours whilst Enterococcus showed proliferation at 25 
o
C. The insulin was retested with 
Enterococcus but with an inoculum prepared with 0.9 % saline. Authors declared these results to be 
inconclusive but the number of organisms at 168 hours were less that the initial inoculum. (47) K. 
pneumoniae survived in heparin up to 24 hours only. The lignocaine showed proliferation of most of 
the test organisms, including K. pneumoniae, when the inoculum was prepared with 0.25 % peptone 
in saline. When retested with 0.9 % saline, lignocaine was found to be bactericidal to K. pneumoniae 
by 24 hours post inoculation.  This study had two significant findings.  Firstly, that a small amount of 
peptone added to pharmaceuticals was sufficient to allow survival or proliferation of bacteria and 
yeasts. It was believed that the peptone either inactivated the preservative or provided sufficient 
nutrients to allow bacterial growth.  The second finding was that bactericidal activity was higher at 25 
o
C than 4 
o
C. (47) 
Longfield, et al tested behaviour of C. freundii, E. aerogenes, E. agglomerans, Flavobacter 
meningosepticum, K. pneumoniae, P. cepacia, S. maltophilia, S. marcescens, S. aureus and S.  
epidermidis in medication in multiple-dose vials. (48) This included insulin, heparin and lignocaine. 
An inoculum of 1000 cfu/mL in saline was used. (48) All experiments were done at 4 
o
C and 22 
o
C. 
The mean time to sterility in insulin was 5.4 hours at 22 
o
C and 25 hours at 4 
o
C, heparin was 5.3 
hours at 22 
o
C and 33.4 hours at 4 
o
C and lignocaine was 15.5 hours at 22 
o
C and 132 hours at 4 
o
C.  
The study showed that whether or not bacteria allow persistence or proliferation depended on the type 
of medication, preservative used, storage temperature and specific risks. Thus, when developing 
guidelines for use of multiple-dose vials, it should be done on product to product basis. (48) 
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Rathod et al, 1985 tested insulin with P. aeruginosa and S. aureus at 22 
o
C and 4 
o
C. (45) Inoculum 
densities of 10
2
, 10
4 
and 10
6 
cfu/mL were used.  Both organisms were eradicated in 24 hours at 22 
o
C 
with all inoculum densities. The bacterial killing was much slower at 4 
o
C. This took 10 days for P.  
aeruginosa with an inoculum of 10
6  
cfu/mL and with S. aureus persistence was demonstrated up to 17 
days.  This study showed that insulin does not get contaminated with pathogens even if the vial was 
used for > 28 days and that the preservative was more effective at 22 
o
C than 4 
o
C. (45) 
Studies investigating contamination of in-use medication have shown that bacterial contamination of 
medication fluids can occur (29, 43, 46, 49) whilst sterility studies showed that the fluids can resist 
bacterial growth (44, 47, 48) but, as evidenced by the outbreaks, medication vials have been identified 
as microbial reservoirs.  (20, 33–35) Healthcare associated infections adversely affect patient safety 
and also have negative impact on costs and resources. Guidelines on safe use of medication vials 
should be evidence based.  
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CHAPTER THREE 
 
AIMS AND OBJECTIVES 
 
3.1 Aim 
To determine the possibility of Klebsiella pneumoniae ATCC 700603 proliferating in multiple-dose 
medication and intravenous fluids 
3.2 Objectives 
1. To determine the growth curve of K. pneumoniae in brain-heart infusion broth  
2. To conduct a microbiological challenge test using K.  pneumoniae of 
a. vials and ampoules containing medication used for multiple-dose intravenous 
administration  
b. intravenous fluids  
3. To determine the minimum number of colony forming units (cfu) of K. pneumoniae that 
results in contamination of medication and intravenous fluids  
4. To determine the concentration of dextrose that allows multiplication of K. pneumoniae  
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CHAPTER FOUR 
 
MATERIALS AND METHODS 
4.1 Ethics Approval 
This research project received approval from the Biomedical Research Committee at the University of 
KwaZulu-Natal. Ethics number: BE 222/13. This research project did not involve collection of 
specimens from patients, healthcare establishment environment or healthcare workers. 
4.2 Study material 
Multiple-dose medication vials and ampoules as well as intravenous fluids commonly used at the 
King Edward VIII Hospital were used in this investigation. King Edward VIII hospital is the second 
largest hospital in the Southern hemisphere, providing regional and tertiary services to the whole of 
KZN and Eastern Cape. It has 922 beds and sees +/- 360 000 out-patients. The hospital is situated in 
the eThekwini District. (50) For all tests Klebsiella pneumoniae ATCC 700603 was used. 
4.2.1 Vials.   
The medication in vials was accessible by piercing a hypodermic needle through a rubber septum. The 
vials tested and their contents included Tazobax®(Aspen, Johannesburg, South Africa) 20 mL with 4g 
piperacillin and 0.50 g tazobactam as sodium salts (51),  Ciprocina®(Claris Life sciences, United 
Kingdom Limited, Cheshire, United Kingdom ) 100  mL ciprofloxacin 2mg /mL  (52), 
Meronem®(AstraZeneca Pharmaceutical, Bryanston, South Africa ) meropenem 500 mg in 20 mL  
(53),  Actrapid HM(ge)®( Novo Nordisk, Sandton, South Africa ) with 100 units/mL genetically 
engineered mono-component neutral insulin, preserved with 0.3 % m-cresol  (54), Heparin Sodium® ( 
Fresenius Kabi, Midrand, South Africa)  with 25000  i.u/mL heparin preserved with chlorocresol 0.1 
% w/v  (55) and  Lignocaine HCL®-( Fresenius Kabi, Midrand, South Africa ) 2 % (w/v) preserved 
with methyl hydroxybenzoate 0.1 % w/v. 
4.2.2 Ampoules 
Ampoules tested included Gentamicin (Aspen, Johannesburg, South Africa ) 80 mg/2 mL  and  
Dextrose 50  %(Fresenius Kabi, Midrand, South Africa )(20 mL).  
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4.2.3 Intravenous Fluids 
Two intravenous fluids were tested. These included Neonatalyte®(Adcock Ingram, Midrand, South 
Africa ) which comprised of Glucose Monohydrate 110  g/L, Potassium Chloride 1.12 g, Calcium 
Chloride Dihydrate 367  mg, Magnesium Chloride Hexahydrate 102 mg, Sodium Lactate 2.0  g and 
Phosphoric Acid 367 mg and Sodium chloride, 0.9  % (Adcock Ingram, Midrand, South Africa ). 
4.3 Method 
4.3.1 Growth curve 
The growth curve of K. pneumoniae ATCC 700603 was determined at: 
 25 oC, which is the median temperature to be maintained in Neonatal Intensive Care 
and nursing units.  The temperature in such units must be maintained at 24-26 
o
C 
(Department of Health: KZN Infection Prevention and Control Guidelines.  (56–58) 
 35 oC, the optimum temperature for growth of K. pneumoniae. (59) 
 
K. pneumoniae was stored in cryovials (Corning, Globe Scientific, Mahwah, Unites States of 
America) at -80 
o 
C ( Nuaire Glacier , Model No NU 9483E, Plymouth, Unites States of America ) in 
the repository at the Department of Medical Microbiology/Infection Prevention and Control. For 
storage, overnight cultures of K. pneumoniae were picked off the agar plate and inoculated into the 
cryovials containing glass beads and a storage broth which comprised of brain heart infusion ( Oxoid 
LTD, Basingstoke, Hampshire, England ) and glycerol ( Merck Chemicals, (Pty) Ltd, Germiston, 
South Africa).  (Appendix C.3) The vials were then gently shaken, allowing the bacteria to coat the 
glass beads. The excess broth was then aspirated and discarded and the vial frozen. 
 
Following thawing of the contents of a cryovial at room temperature, one glass bead was aseptically 
removed and rolled onto a Columbia Blood Agar plate ( Oxoid LTD, Basingstoke, Hampshire, 
England )  with 5 % horse blood (Appendix C.2). Following inoculation, the plates were incubated 
overnight, aerobically at 35 
o
C.  
4.3.1.1 Inoculum Preparation / Growth Curve 
The next day, one colony was touched with a sterile straight wire and inoculated in 5 mL of brain 
heart infusion broth.  (Appendix C.5) The broth was then incubated overnight, under aerobic 
conditions at 35 
o
C. Of this overnight culture, 100 µL was inoculated into a 50 mL polypropylene tube 
( Greiner Bio-One GmgH, Frickenhausen, Germany ) containing 45 mL of brain heart infusion broth. 
( Oxoid LTD, Basingstoke, Hampshire, England ). The tube was then inverted to mix the culture. 
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To determine the optical density, two cuvettes ( Kartell Labware, Usmate, Italy ) were used.  One 
containing 2 mL of sterile brain heart infusion broth was used as a blank, the other as test cuvette. The 
test cuvette was filled with 1800 µL of brain heart infusion broth and 200 µL of the freshly inoculated 
suspension in brain heart infusion broth. The optical density was obtained at a wavelength of 600 nm 
using the Biochrom, Lightwave 11 Spectrophotometer, Model 80-3003-72, Cambridge, United States. 
.  Readings were done in triplicate and the average thereof was taken as the final reading. Readings 
were taken every half an hour up to ten hours. 
 
Incubation was under aerobic conditions at 25 
o
C or 35 
o
C for the length of the experiment. Incubation 
commenced after the first readings were taken. Sterile, 2 mL, microcentrifuge tubes ( Eppendorf, 
Hamburg, Germany ) were used. Nine hundred µL of phosphate buffered saline (Oxoid LTD, 
Basingstoke, Hampshire, England) (Appendix C.4) was inoculated into each tube. One hundred µL of 
the brain heart infusion culture was then inoculated into the 900µL of phosphate buffered saline to 
give a dilution factor of 1:10. 
Ten serial 1:10 dilutions were then performed. This was done by aspirating 100 µL from the first tube 
and inoculating into the next. The tube was then closed and vortexed for 30 seconds. 
 ( Velp®Scientifica, Model No/code F202A0230, Usmate, Italy )  One hundred µL from this tube was 
then aspirated and inoculated into the next tube. This was then continued until the last tube was 
reached. One hundred µL from each dilution was then inoculated onto a labelled MacConkey plate ( 
Oxoid Ltd, Basinstoke, and Hampshire, England ) (Appendix C.1). The inoculum was spread using 
disposable loops ( Sterilin,  Scientific Laboratory Supplies Ltd, Scotland, United Kingdom ).  The 
plates were incubated overnight, under aerobic conditions at 35 
o
C. 
 
The next morning, the plates were read to count the colonies.  Plates with a number of colonies 
between 20 and 200 (60) were counted. This value was then corrected for the dilution factor to 
determine the actual number of cfu at each time point. The experiment was done in triplicate at both 
incubation temperatures.  
4.3.2 Microbiological challenge test 
4.3.2.1 Preparation of the inoculum 
K. pneumoniae was inoculated onto MacConkey Agar and subjected to the four way streak method to 
obtain single colonies. (61) The plates were then incubated overnight, aerobically at 35 
o
C.  The next 
morning, one colony was touched and inoculated into 5 mL of brain heart infusion broth. The tube 
was incubated aerobically at 35 
o
C up to an OD of 1.5. The optical density was determined at a 
wavelength of 600 nm using a spectrophotometer.  An OD of 1.5 yielded approximately 1.2x10
9
 
cfu/mL.  The culture was then washed using phosphate buffered saline in order to remove all traces of 
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the broth as the broth could provide nutrients necessary to promote the growth of the organism. This 
was done three times at 4400 rpm for 3 minutes per spin. ( Eppendorf centrifuge, Model No 
570207910, Hamburg, Germany ). After the final spin, the phosphate buffered saline was decanted 
into a bucket containing disinfectant.  The pellet was then re-suspended in 5 mL of phosphate 
buffered saline. Five serial 1:10 dilutions were then performed to yield approximately 1.2-1 x 10
4  
cfu/mL.  One hundred µL was used thus deriving and inoculum density of   approximately 1.2-1 x 10
3  
cfu. (62)  
 
Before the actual simulated contamination of the test vials, it was first established that the fluid in the 
vials was not contaminated. This was confirmed by culture.  The vial rubber septa and intravenous 
ports were swabbed with 70 % alcohol and allowed to dry. A sterile 2 mL syringe (Avacare, Supra 
Healthcare, Johannesburg, South Africa ) with a 26G x1 needle ( duraSurge, Omnisurge, 
Johannesburg, South Africa) was used for each vial and intravenous fluid bag. Five hundred µL from 
the vials and 1 mL from the intravenous fluid bags were aspirated and inoculated onto MacConkey 
plates. The plates were incubated overnight, aerobically at 35 
o
C.  
 
One hundred µL of the K. pneumoniae suspension was dispensed on each vial rubber septum and on 
the rubber septa of the bag ports. The septa were allowed to dry. Vials and bags were sampled with a 
different sterile syringe without disinfection:  every half an hour for eight hours on the day of 
contamination and 24 hours post inoculation.  At each time point 500 µL was aspirated from each vial 
and 1mL from each bag. The aspirates were inoculated onto MacConkey plates. These plates were 
incubated overnight, under aerobic conditions at 35 
o
C. The next morning, colonies were counted. 
Tests were done in triplicate. 
 
The ampoules containing 50 % dextrose ampoule and gentamicin were tested differently and also 
conducted in triplicate. One hundred µL of the K. pneumoniae suspension was dispensed on a gloved 
thumb and spread using the tip of the pipette ( Gilson, Middleton, United States of America ). The 
ampoules were then opened using this thumb. The ampoules were left open and sampled at same time 
points as for vials and bags.  Five hundred µL was aspirated from the dextrose and hundred µL from 
the gentamicin ampoules. The aspirates were inoculated onto MacConkey plates. These plates were 
then incubated overnight, under aerobic conditions at 35 
o
C, after which colonies were counted. 
 
At the end of the last sampling, an impression culture was done on MacConkey agar. Figure 1 shows 
the appearance of the rubber septa after the sampling episode. The rubber septa of the vials and the 
ports of the bags were pressed onto the agar plate. The plates were incubated overnight, aerobically at 
35 
o
C after which colonies were counted. 
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Figure 1: Appearance of the vial septum after sampling episodes 
 
4.3.3 Minimum inoculum for growth in different medication fluids 
 
To define the minimum number of cfu of K. pneumoniae that results in contamination of insulin 
heparin, lignocaine, Neonatalyte® and saline. 
 
 A bacterial suspension prepared as described in 4.3.2.1 was then diluted to yield approximately 
20000 cfu/mL, followed by five two-fold serial dilutions, resulting in test inocula of 20000, 10000, 
5000, 2500, 1250 and 625 cfu/mL. Of each of the test fluids, 1900 µL was pipetted in six well of a 24-
well tissue culture plate. Hundred µL of each test inoculum was added to one of these wells. This was 
done twice in triplicate. One set of plates was incubated at 25 
o
C and one at 35 
o
C. Figure 2 and 3 
depicts the set up experiments.   
 
To measure increase in number of bacteria during incubation, 100 µL of each well was flooded onto a 
MacConkey agar immediate after inoculation, after 0.5 hours and every hour for 8 hours. The last 
sampling was after 16 hours. These MacConkey agars were incubated overnight, aerobically at 35 
o
C. 
The next day, the numbers of colonies were counted. 
 
. 
 
Piercings on the rubber septum 
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Figure 2: 24 well tissue culture plate with K. pneumoniae inocula in medication fluids  
                                                                                                                                                
 
Figure 3: Illustration of a 24 well tissue culture plate with K. pneumoniae  inocula in  saline  
4.3.4 Effect of dextrose concentration on growth of K. pneumoniae 
To determine the effect of various concentrations of dextrose on the growth of K. pneumoniae. 
 
For the first experiment (experiment A), four two-fold serial dilutions of 50 % dextrose were made in 
24 well tissue culture plates using sterile distilled water as diluent. Final concentrations were 50 %, 25 
%, 12.5 % and 6.25 % in 1900 µL volumes. The 6 wells of each row contained the same dextrose 
concentration (Figure 4 )  
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For the second experiment (experiment B), 1900 µL of 10 % dextrose solution in distilled water was 
dispensed in the wells of the first row of a 24-well tissue culture plate, 1900 µL of 3 % in the second 
row and  of 1900 µL 2 % in the third row (Figure 5). 
 
 Figure 4: Illustration of a 24 well tissue culture plate with K. pneumoniae inocula in dextrose  
 
        
Figure 5: Illustration of a 24 well tissue culture plate with K. pneumoniae inocula in dextrose  
The K. pneumoniae (ATCC 70063) suspension was prepared as described above 4.3.2.1. Two-fold 
serial dilutions were made resulting in suspensions with six different concentrations of approximately 
20000, 10000, 5000, 2500, 1250 and 625 cfu/mL respectively. To the wells of each column of the 
tissue culture plates A and B, 100 µL of the six K. pneumoniae suspensions was added (Figure 4 and 
5 ).   
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Samples of 100 µL were taken from each well at 0.5 hour and at 1 hour post inoculation. This was 
followed by hourly sampling for up to eight hours and then after 16 hours. Samples were inoculated 
onto a MacConkey plate and spread out using disposable loops. All plates incubated overnight, 
aerobically at 35 
o
C. The next day colonies were counted. 
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CHAPTER FIVE 
 
RESULTS 
5.1 Growth curve and turbidity standard curve for Klebsiella pneumoniae.  
K. pneumoniae ATCC 700603 was incubated aerobically in brain heart infusion broth at 25 
o
C and 35 
o
C.  The number of colony forming units per mL and turbidity at OD600 was assessed over a 10 hour 
period. The data were used to compare growth rates at 25 
o
C and 35 
o
C and to construct a turbidity 
standard curve at both temperatures. These standard curves allowed turbidity values to be used instead 
of more labour intensive colony counts in the experiments to follow. 
Figure 6 shows both growth curves at 25 
o
C and 35 
o
C. At both temperatures, the curve starts with a 
lag phase of 2 hours at 35 
o
C and 3 hours 25 
o
C. This was followed by exponential growth at both 
temperatures resulting in log phases that run in parallel.   At 25 
o
C, a delay before the exponential 
phase is observed, whereas at 35 
o
C, the exponential phase commences more sharply. Since the aim of 
this experiment was to establish the correlation between turbidity and bacterial concentration, the 
incubation was stopped at the end of the exponential phase. 
 
 
Figure 6: Growth curve of K. pneumoniae at 25  
o
C and 35 
o
C 
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Figures 7 and 8 shows the relationship between cfu/mL and OD600 readings in the log phase of growth 
at 25 
o
C and 35 
o
C.  The cells in the suspension cause the light to scatter. (63) As the number of cells 
increase, the scatter of light also increases and with that, the OD reading. Both graphs show the 
expected linear relationship between the two values. 
 
Figure 7: Relationship between optical density at 600 nm and cfu/mL at 25 
o
C 
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Figure 8: Relationship between optical density at 600 nm and cfu/mL at 35 
o
C 
An OD of 1.5 was used for all experiments. This corresponds with approximately 1.2 x10
9
 cfu/mL, 
independent of the incubation temperature. For each experiment this suspension was diluted till the 
required number of cfu/mL. 
5.2 Microbiological challenge test 
Table 1 shows the quantitative culture results of the challenge tests.  K. pneumoniae was isolated up to 
1 hour post contamination of the rubber septa of the insulin, heparin, lignocaine, Neonatalyte® and 
saline.  In all five, the number of cfu/mL decreased over time, reaching 0 cfu/mL in 1.5 hours post 
contamination with four of five products. With insulin, growth was only observed after 0.5 hours. 
With piperacillin-tazobactam, ciprofloxacin and meropenem as well as with gentamicin and 50 % 
dextrose no growth was observed at any time point 
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Table 1: Quantitative culture results (cfu/mL) of the challenge tests 
 Insulin Heparin Lignocaine Neonatalyte® Saline 
Time in (Hr)      
0.5 8 46 22 45 12 
1 0 2 12 1 2 
1.5 0 0 0 0 0 
 
Results of the challenge tests at all time points are shown in appendix D. 
The impression cultures of the rubber septa of the vials and intravenous ports of intravenous fluids 
showed no growth at 24 hours post experimental contamination. 
5.3 K. pneumoniae inoculated in medication fluids  
Tables 2 and 3 show the results. Insulin, heparin and lignocaine failed to support the growth of K. 
pneumoniae. When inoculated with 1000 cfu/mL, the bacterial density at 25 
o
C decreased by 65 %, 33 
% and 20 % respectively whereas at 35 
o
C, the cfu/mL decreased with 83 %, 97 % and 81 % 
respectively. The bactericidal activity of these solutions is presented in tables two and three. In 5000 
IU/mL of heparin, the bacterial count declined in the first 30 minutes rapidly to 670 cfu/mL and 33 
cfu/mL at 25 
o
C and 35 
o
C respectively. It took an additional 5.5 hours and 1.5 hours for the 
remaining 67 % and 7 % of the inoculum to be killed. This rapid decline in the first 30 min. was also 
seen with insulin and lignocaine but the percentage survival at 30 min at 25 
o
C was 35% for insulin 
and 80 % for lignocaine. At 35 
o
C these figures were lower: 17 % and 19 % respectively. At 25 
o
C, no 
growth was detected at 6 hours post inoculation in insulin and at 7 hours post inoculation in 
lignocaine whereas at 35 
o
C, no growth was detected in insulin and lignocaine at 5 hour and 4 hours 
respectively.  Full results are provided in Appendix E. 
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Table 2: K. pneumoniae inocula in insulin, heparin, lignocaine, Neonatalyte® and saline at 25 
o
C. 
The cfu/mL and the percentage survival at each time point are shown below.  
  Insulin Heparin Lignocaine Neonatalyte Saline 
Time(Hrs) cfu/mL 
% 
survive cfu/mL 
% 
survive cfu/mL 
% 
survive cfu/mL 
% 
survive cfu/mL 
% 
survive 
0.5 350 35 670 67 800 80 900 90 950 95 
1 120 12 500 50 760 76 908 91 900 90 
2 90 9 450 45 400 40 903 90 910 91 
3 80 8 300 30 233 23 900 90 870 87 
4 50 5 100 10 108 11 908 91 900 90 
5 30 3 40 4 87 9 900 90 910 91 
6 0 0 40 4 3 0.3 899 90 920 92 
7 0 0 30 3 0 0 970 97 950 95 
8 0 0 0 0 0 0 800 80 900 90 
24 0 0 0 0 0 0 2860 286 890 89 
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Table 3: K. pneumoniae inocula in insulin, heparin, lignocaine, Neonatalyte® and saline at 35 
o
C  
The cfu/mL and the percentage survival at each time point are shown below. 
 
 
In Neonatalyte®, there was an initial decrease of 10 % and 37 % in the cfu/mL at 25 
o
C and 35 
o
C 
respectively.  At both temperatures, the bacterial density then remained constant up to 8 hours post 
inoculation.  Between 8 and 24 hour an increase in cfu/mL of 286 % and 413 % was detected in at 25 
o
C and 35 
o
C respectively. 
 
In saline, there was a decrease in the cfu/mL of 5 % and 23 % at 25 
o
C and 35 
o
C respectively.  
Thereafter, the cfu/mL remained constant up 24 hours post inoculation. No increase in bacterial 
density was observed.  
 
The results are shown in Appendix E. 
 
 
 
Time(Hrs) cfu/mL % survive cfu/mL % survive cfu/mL % survive cfu/mL % survive cfu/mL % survive
0.5 173 17 33 3 190 19 630 63 773 77
1 57 6 3 0.3 153 15 757 76 603 60
2 33 3 0 0 87 9 690 69 533 53
3 7 0.7 0 0 5 0.5 710 71 507 51
4 3 0.3 0 0 0 0 700 70 591 59
5 0 0 0 0 0 0 780 78 520 52
6 0 0 0 0 0 0 720 72 487 49
7 0 0 0 0 0 0 640 64 533 53
8 0 0 0 0 0 0 783 78 503 50
24 0 0 0 0 0 0 4130 413 750 75
Insulin Heparin Lignocaine Neonatalyte Saline
27 
 
 
5.4 Dextrose concentration and growth of K. pneumoniae 
Viability of the K. pneumoniae in dextrose 
The behaviour of K. pneumoniae was studied in various concentrations of dextrose. This was assessed 
over a 24 hour period at 25 
o
C and 35 
o
C. The results with an inoculum of 1000 cfu/mL are shown in 
tables 4 and 5. Full results are in appendix F.  
Bactericidal activity was observed in 50 %, 25 % and 12.5 % dextrose at both incubation 
temperatures. In 50 % dextrose a reduction in colony count of 39 % was observed after 30 min at 25 
o
C and of 57 % at 35 
o
C.  In 25 % dextrose, there was no change in the bacterial density and in 12.5 % 
dextrose, a slight decrease in the bacterial density of 5 % at 25 
o
C and 6 % at 35 
o
C was observed.    
No growth was observed in 50 %, 25 % and 12.5 % dextrose at 25 
o
C in 3 hours, 4 hours and 24 hours 
post inoculation respectively whereas at 35
o
C, this was observed in 4 hours and 5 hours in 50 % and 
25 % dextrose respectively. No growth was also observed 24 hours post inoculation in 12.5 % 
dextrose at 35
o
C as well.   
In 10 % dextrose, there was no change in the bacterial density in 30 min. In one hour, there was a 
decrease in the cfu/mL of 32 % and 1 % at 25 
o
C and 35 
o
C respectively. Thereafter, a gradual 
decrease in the bacterial density was observed.  At 24 hours post inoculation, a decrease of 57 % and 
50 % was observed at 25 
o
C and 35 
o
C respectively. 
In the lower concentration of dextrose of 6 %, 3 % and 2 %, there was an initial decrease in the colony 
counts at both temperatures up to 8 hours post inoculation. At 25 
o
C, the decrease in the colony count 
ranged from 1-13 % and at 35 
o
C, this was 1-22 %. After 24 hours post inoculation at 25 
o
C, in the 6 
%, 3 % and 2 % the colony counts increased by 12 %, 24 % and 33 % respectively. At 35
o
C, slightly 
higher increases were observed with 20 % in the 6 % dextrose and 34 % in the 3 % dextrose at 24 
hours post inoculation.  The 2 % dextrose, however, showed a 1 % increase in the bacterial density by 
6 hours post inoculation and by 24 hours post inoculation 50 % increase in cfu/mL.     
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Table 4: K. pneumoniae inocula in dextrose at 25 
o
C  
The number of cfu/mL and percentage survival is shown in the table below. 
 
 
50 % 25 % 12.50 % 10 % 6 % 3 % 2 % 
Time(Hr) cfu/mL % cfu/mL % cfu/mL % cfu/mL % cfu/mL % cfu/mL % cfu/mL % 
0.5 610 61 1000 100 950 95 1000 100 950 95 980 98 990 99 
1 550 55 610 61 810 81 680 68 980 98 980 98 910 91 
2 50 5 520 52 540 54 660 66 870 87 970 97 940 94 
3 0 0 40 4 520 52 640 64 880 88 980 98 980 98 
4 0 0 0 0 560 56 640 64 890 89 990 99 980 98 
5 0 0 0 0 560 56 590 59 910 91 910 91 960 96 
6 0 0 0 0 430 43 570 57 940 94 940 94 940 94 
7 0 0 0 0 480 48 590 59 980 98 980 98 980 98 
8 0 0 0 0 300 30 450 45 980 98 980 98 990 99 
24 0 0 0 0 0 0 430 43 1120 112 1240 124 1330 133 
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Table 5: K. pneumoniae inocula in dextrose at 35 
o
C  
The number of colonies and percentage survival is shown in the table below 
 
  50 % 25 % 12.50 % 10 % 6 % 3 % 2 % 
Time(Hr) cfu/mL % cfu/mL % cfu/mL % cfu/mL % cfu/mL % cfu/mL % cfu/mL % 
0.5 430 43 1000 100 940 94 1000 100 880 88 980 98 910 91 
1 230 23 430 43 750 75 990 99 800 80 940 94 980 98 
2 70 7 230 23 470 47 960 96 780 78 950 95 980 98 
3 10 1 70 7 410 41 930 93 900 90 910 91 970 97 
4 0 0 10 1 440 44 760 76 900 90 930 93 960 96 
5 0 0 0 0 480 48 680 68 940 94 990 99 980 98 
6 0 0 0 0 380 38 640 64 930 93 980 98 1010 101 
7 0 0 0 0 320 32 620 62 930 93 970 97 1200 120 
8 0 0 0 0 360 36 600 60 940 94 980 98 1180 118 
24 0 0 0 0 0 0 500 50 1200 120 1340 134 1500 150 
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CHAPTER SIX 
 
DISCUSSION 
Patient safety forms an essential part of ensuring quality healthcare and is the foundation of a strong 
system. (64)  The World Health Organisation(WHO) states that, “Unsafe medication practices and 
medication errors are a leading cause of injury and avoidable harm in health care systems across the 
world.” (65) In medical practice, medications are often administered via injections. (66) Micro-organisms 
can easily be introduced into the blood stream or tissues in this way. A safe injection does not harm the 
recipient, does not expose the provider to any avoidable risks and does not result in waste that is 
dangerous for the community or the environment. (66)  
 Multiple-dosing of single use medication is a dangerous practice. Medications meant for single dosing do 
not have a preservative. Depending on the constituents of the medication fluids and concentration, these 
medication fluids may allow bacterial growth or bacterial persistence such as Neonatalyte® and isotonic 
solution. (67) 
Experiments that determine behavior of organism in medication fluids require that these organisms are in 
the log phase of growth at the time of inoculation. The traditional colony counting method to determine 
inoculum sizes takes two to three days. In this method ten-fold serial dilution of the culture are plated, 
incubated and counted. By the time the cfu/mL is determined the culture is no longer in the log phase. 
(68) Figures 7 and 8 shows a linear relationship of Klebsiella pneumoniae, in the log phase, between 
OD600 and cfu/mL.  Zhang et al  had similar findings. (68) Authors used three strains of Gram-negative 
bacteria (Escherichia coli, K. pneumoniae, and Pseudomonas aeruginosa) and three strains of Gram-
positive bacteria (Staphylococcus aureus, Enterococcus faecium, and Bacillus subtilis) to construct 
growth curves. (68) 
Table 1 show the results of the microbiological challenge test. It is possible that the organisms isolated 
were either from the rubber septa and medication bag ports or the medication fluid. The septa of 
medication vial are designed to have a self-sealing ability and in the case of multiple-dose vials, be able to 
withstand multiple withdrawals. (27)  It is most probable that the organisms were from the rubber septa.  
When determining the growth kinetics of K. pneumoniae in fluids containing preservatives; (insulin, 
heparin and lignocaine) the fluids showed bactericidal activity at both incubation temperatures. The 3 log 
reduction meets the standards for antimicrobial effectiveness. (69, 70) The bactericidal activity 
demonstrated at 25 
o
C indicates that these vials can be safely stored at this temperature. Bactericidal 
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activity of preservative containing medication was also demonstrated by Highsmith et al (47). However, 
in this study an extended persistence of K. pneumoniae of up to 24 hours post inoculation was found in 
lignocaine. Longfield et al (48) demonstrated a mean bacterial killing time of 5.3 hours in insulin, 5.4 
hours in heparin and 15.5 hours in lidocaine. This study showed an even faster time to sterility in 
lignocaine. When stored at the recommended storage temperatures, these medications have not shown 
contamination. A study has shown that storage of multiple-dose vials at 4 
o
C adversely affects the 
bacterial activity of the preservative. (12) Because of this finding, multiple-dose vials stored in the 
refrigerator have been hypothesized to be the source of outbreaks. (12) The current KwaZulu-Natal 
(KZN) policy recommends that multiple-dose vials be stored in a refrigerator at 4 
o
C. (10) This policy 
requires revision to specify storage at room temperature or as stipulated by the manufacturer. 
Heparin is a mucopolysaccharide composed of partially sulfated units of glucuronic acid and 
aminodeoxyglucose. (71) Rosett et al showed the ability of heparin to inhibit the growth of 
microorganisms. (72)  It was hypothesized that heparin binds cations essential for bacterial growth. (72)  
Whilst the antibacterial activity of heparin has been demonstrated, contamination by other micro-
organisms was not excluded.  Saigul et al (73) reported that a young girl was infected with Plasmodium 
falciparum after she received heparin from a multiple-dose vial. The heparin solution was contaminated 
as a result of re-use of syringes. The syringe was contaminated with blood from a malaria patient. The 
infected blood was then introduced into the vial and subsequently into the patient. (73) The preservative 
used in heparin is not effective against protozoa. Proteins are able to inactivate preservatives and provide 
bacteria with nutrition necessary for growth.  A combination of these factors could have resulted in 
pathogenic reservoirs in medication vials.  
Fluids meant for multiple-dosing contain preservatives. Provided these vials were used and stored in 
accordance with the manufacturer’s instructions, contamination rates remain low.  (74) The one vial, one 
patient approach is the safest. In low resource settings, where this is not feasible, clear guidelines must be 
provided for safe use of medication fluids with consideration on a product to product basis.  
Administration of intravenous fluid can provide an opportunity for introduction of bacteria into the blood 
stream. Bacteria can enter the fluid during preparation of the medication, administration of the medication 
and subsequent handling of the bag and ports. These medications do not contain preservatives and thus 
present as a major risk factor for blood stream infections. The ability of K. pneumoniae to persist in 
Neonatalyte® and in saline must be considered when developing guidelines. Due to the volume of the 
bags, these fluids are often used for multiple-dosing in paediatric patients. (26) The current KwaZulu-
Natal policy allows multiple-dosing of preservative free, single use medications, provided withdrawals 
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are made one after the other. (10) Outbreaks have been reported with heparin/saline flushes and multi-
dosing of Neonatalyte® and saline. (31, 34, 39, 75)  Bacteria inadvertently introduced into these bags can 
cause healthcare associated infection and outbreaks. It is critical that this policy be revised into single 
patient, single use. Health care professionals must be made aware of the risks. 
 Fifty percent, 25 %, 12.5 % and 10 % dextrose solutions are hypertonic. The hypertonic nature of the 
solution can draw fluid out of the bacterial cell, leading to dehydration of bacteria and eventual death. The 
12.5 % solution of dextrose allowed persistence of K. pneumoniae up to 8 hours, whilst 10 % allowed 
persistence for up to 24 hours.  
The lower concentrations are isotonic in nature. The cellular integrity is thus not affected by the solution. 
Also, utilisation of carbon is said to be optimal in a glucose/dextrose limited environment.  (76) These 
two factors could account for the increase in cfu/mL. The log increase at 25
o
C in 6 % dextrose was 0.04, 
in 3 % 0.09 and in 2 % was 0.12. Lack of bacterial growth is defined as no more than a 0.5-log10 increase. 
(70, 77) Therefore, the increases in cfu/mL in these low dextrose concentrations are not regarded bacterial 
growth. Whilst this solution allows for metabolism, it does not promote rapid proliferation. Survival of K. 
pneumoniae is inversely related to the concentration of dextrose.  
Dextrose is used for management of hypoglycaemia and in total parenteral nutrition (TPN). In paediatrics, 
dextrose is used at concentrations of 2.5 to 10 %. (78) At both concentrations, bacteria persist. Results 
similar to ours were reported by Hugbo et al. (67) In that study, K. pneumoniae decreased with increasing 
dextrose concentrations. C. albicans was also included in the panel of test organisms and the cell count of 
that organism remained constant at all dextrose concentrations.  The conclusion reached was that with 
bacteria, the extent of inhibition of growth was dependent on the dextrose concentration, incubating 
conditions and pH of dextrose solutions whereas yeasts are not affected by dextrose concentration. (67)  
This study tested only K. pneumoniae ATCC 700603. This is a well characterised extended spectrum beta 
lactamase producer. This organism was chosen because in KZN, this is the sole cause of outbreaks due to 
the use of medication. In future, the study should be extended with other micro-organisms as well as with 
surveillance studies of in-use vials to assess contamination rates in the health care setting.  
Whilst proliferation has not been demonstrated, persistence of the test bacteria in isotonic saline, 
Neonatalyte® and lower concentrations of dextrose has been shown. This poses serious risk to patient 
care if the bacteria inadvertently enter the fluid due to infection prevention breeches. 
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APPENDIX C 
Media Preparation 
1.  Maconkey agar (CM007) Oxoid, Basingstoke, Hampshire, England) 
a. Constituents 
i. MacConkey agar powder 52 g 
ii. Distilled water 1 L 
b.  Method 
i. 52 g of Maconkey agar powder was weighed( Radwag Model: WTB 2000, 
Radom, Poland )and transferred into a glass flask 
ii. 1L of distilled water was measured and added to the flask 
iii. The flask was swirled until the powder was well dissolved 
iv. The opening of the flask was then covered with an acceptor bag and taped with 
autoclave tape 
v. The media was then autoclaved at 121 oC ( Sterilizer Technologies SD 158) for 
15 min 
vi. The flask was then placed in a water bath at 55oC for approximately one hour or 
until cool enough to touch 
vii. Using a media dispenser ( Jencon Perimatic GP Model: GP1, Bridgeville, Unites 
States of America )and aseptic procedure, 20 mL  of the media was dispensed 
into 90 mm petri dishes( Concorde Plastics (Pty) Ltd, Longdale, Johannesburg, 
South Africa ) 
2. 5 % Horse  Blood agar 
a. Constituents 
i. Columbia Blood agar base powder 39 g 
ii. Distilled water 1 L 
iii. Horse Blood 50mL 
b. Method 
i. 30 g of Columbia Blood agar base (CM0331)( Oxoid, Basingstoke, Hampshire, 
England ) was weighed and transferred into a glass flask 
ii. 1L of distilled water was measured and added to the flask 
iii. The flask was swirled until the powder was well dissolved 
iv. The opening of the flask was then covered with an acceptor bag and taped with 
autoclave tape 
v. The media was then autoclaved at 121 oC for 15 min 
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vi. The flask was then placed in a water bath at 55 oC for approximately one hour or 
until cool enough to touch 
vii. Using a media dispenser and aseptic procedure, 20 mL  of the media was 
dispensed into 90 mm petri dishes 
3.  Storage media 
a. Constituents 
i. Brain Heart Infusion (BHI)broth 12 g 
ii. Distilled water 400 mL 
iii. Glycerol 100 mL 
iv. Glass beads 
b. Method 
i. 12 gr of BHI ( Oxoid, Basingstoke, Hampshire, England )  powder was weighed 
and transferred into a glass screw cap bottle(Pyrex) 
ii. 400 mL of distilled water was measured and added to the glass bottle 
iii. The bottle was swirled until the powder was well dissolved 
iv. 100 mL of glycerol was then added to the bottle 
v. The  bottle was loosely closed   and taped with autoclave tape from the cap to the 
bottle 
vi. The media was then autoclaved at 121 oC for 15 min 
vii. The media was then cooled 
viii. The cryovials were then  aseptically filled halfway with the glass beads 
ix. 1000 mL of the storage media was dispensed into the cryovials with beads. 
x. Vials were then stored between 2 o-8  oC 
 
4. Phosphate buffered Saline(DulbeccoA), ( Oxoid, Basingstoke, Hampshire, England ) 
a. Constituents 
i. Phosphate Buffered Saline tablets 
ii. 500 mL distilled water 
b. Method 
i. 500 mL of distilled water was dispensed in  screw cap glass bottle 
ii. 5 tablets of phosphate buffered saline(PBS) was then added 
iii. The bottle was swirled until well dissolved 
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iv. The bottle was then loosely capped and an autoclave tape was placed from the 
cap to the bottle 
v. The bottle was sterilised at 115 oC for 10 min 
vi. Once cooled, the 5mL PBS was aseptically dispensed into white screw cap tubes 
( Whitehead Scientific, Cape Town) 
 
5. Brain Heart Infusion(BHI)(CM135)-(Oxoid, Basingstoke, Hampshire, England) 
a. Constituents 
i. 37g of BHI Powder 
ii. 1L of distilled water 
b. Method 
i. 1000 mL of distilled water was dispensed in  screw cap glass bottle 
ii. 37g of BHI powder was added to the glass bottle 
iii. The bottle was swirled until well dissolved 
iv. The bottle was then loosely capped and an autoclave tape was placed from the 
cap to the bottle 
v. The bottle was sterilised at 121 oC for 15 min 
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APPENDIX D 
Table 6: This table illustrates the number of colonies isolated at each time point in cfu/mL. The time point is indicated in hours-post spiking. 
 
Tazobax Ciprocina Meronem Insulin Heparin 
Dextrose  
50% 
Gentamycin Neonalyte® NaCl Lignocaine 
Time: 
(Hr)           
0.5 0 0 0 8 46 0 0 45 12 22 
1 0 0 0 0 2 0 0 1 2 12 
1.5 0 0 0 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 0 0 0 
2.5 0 0 0 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 0 0 0 
3.5 0 0 0 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 0 0 0 
4.5 0 0 0 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 0 0 0 
5.5 0 0 0 0 0 0 0 0 0 0 
6 0 0 0 0 0 0 0 0 0 0 
6.5 0 0 0 0 0 0 0 0 0 0 
7 0 0 0 0 0 0 0 0 0 0 
7.5 0 0 0 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 0 0 0 
24 0 0 0 0 0 0 0 0 0 0 
 46 
 
 
APPENDIX E -Table 7:  K. pneumoniae inocula in insulin at 25 
o
C and 35 
o
C.   
The cfu/mL and the percentage survival at each time point are shown below. 
 
cfu/mL 1000 500 250 125 62 31 
Time 
(Hrs)                         
 
25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 
0.5 350 173 300 150 80 30 20 10 10 3 0 0 
1 120 57 276 124 50 10 1 0 4 0 0 0 
2 90 33 100 50 4 0 0 0 0 0 0 0 
3 80 7 90 45 0 0 0 0 0 0 0 0 
4 50 3 100 33 0 0 0 0 0 0 0 0 
5 30 0 96 21 0 0 0 0 0 0 0 0 
6 0 0 9 0 0 0 0 0 0 0 0 0 
7 0 0 0 0 0 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 0 0 0 0 0 
24 0 0 0 0 0 0 0 0 0 0 0 0 
 
 
 
 
Table 8: K. pneumoniae inocula in heparin at 25 
o
C and 35 
o
C .  
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The cfu/mL and the percentage survival at each time point are shown below. 
 
cfu/mL 1000 500 250 125 62 31 
Time:Hrs 
            
 
25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 
0.5 670 33 403 201 230 115 100 50 23 10 12 6 
1 500 3 190 90 90 45 0 2 0 0 1 0 
2 450 0 45 21 8 4 0 0 0 0 0 0 
3 300 0 10 5 0 0 0 0 0 0 0 0 
4 100 0 4 2 0 0 0 0 0 0 0 0 
5 40 0 0 0 0 0 0 0 0 0 0 0 
6 40 0 0 0 0 0 0 0 0 0 0 0 
7 30 0 0 0 0 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 0 0 0 0 0 
24 0 0 0 0 0 0 0 0 0 0 0 0 
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Table 9: K. pneumoniae inocula in lignocaine at 25 
o
C and 35 
o
C  
The cfu/mL and the percentage survival at each time point are shown below. 
 
cfu/mL 1000 500 250 125 62 31 
Time:Hrs 
            
 
25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 
0.5 800 190 300 145 200 100 100 30 8 0 1 0 
1 760 153 190 110 180 87 0 2 0 0 1 0 
2 400 87 90 40 130 65 0 0 0 0 0 0 
3 233 5 8 4 90 45 0 0 0 0 0 0 
4 108 0 4 1 2 0 0 0 0 0 0 0 
5 87 0 0 0 1 0 0 0 0 0 0 0 
6 3 0 0 0 0 0 0 0 0 0 0 0 
7 0 0 0 0 0 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 0 0 0 0 0 
24 0 0 0 0 0 0 0 0 0 0 0 0 
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Table 10:  K. pneumoniae inocula in Neonatalyte® at 25 
o
C and 35 
o
C 
The cfu/mL and the percentage survival at each time point are shown below 
cfu/mL 1000 500 250 125 62 31 
Time:Hrs 
            
 
25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 
0.5 900 630 489 450 209 230 100 128 8 6 1 9 
1 908 757 450 430 180 201 6 110 0 2 1 0 
2 903 690 350 420 130 190 0 67 0 0 0 0 
3 900 710 490 439 90 87 0 9 0 0 0 0 
4 908 700 510 398 2 56 0 0 0 0 0 0 
5 900 780 530 386 1 0 0 0 0 0 0 0 
6 899 720 348 365 0 0 0 0 0 0 0 0 
7 970 640 450 378 0 0 0 0 0 0 0 0 
8 800 783 540 459 0 0 0 0 0 0 0 0 
24 2860 4130 509 430 0 0 0 0 0 0 0 0 
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Table 11: K. pneumoniae inocula in saline at 25 
o
C and 35 
o
C  
The cfu/mL and the percentage survival at each time point are shown below. 
cfu/mL 1000 500 250 125 62 31 
Time:Hrs 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 
0.5 950 773 475 498 200 256 100 135 30 56 1 9 
1 900 603 400 458 200 250 90 110 45 34 1 0 
2 910 533 425 415 190 189 90 109 2 2 0 0 
3 870 507 375 425 180 176 80 98 1 0 0 0 
4 900 591 300 309 170 165 0 45 0 0 0 0 
5 910 520 275 320 165 150 0 4 0 0 0 0 
6 920 487 250 289 150 245 0 0 0 0 0 0 
7 950 533 225 289 160 230 0 0 0 0 0 0 
8 900 503 220 296 170 235 0 0 0 0 0 0 
24 890 750 200 398 160 230 0 0 0 0 0 0 
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APPENDIX F 
Table 12:  K. pneumoniae inocula in 50 % dextrose  at 25 
o
C and 35 
o
C.  
The cfu/mL and the percentage survival at each time point are shown below 
 
cfu/mL 1000 500 250 125 62 31 
Time:Hrs 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 
0.5 610 430 113 203 93 87 47 17 17 10 0 0 
1 550 230 57 87 7 13 0 0 0 0 0 0 
2 50 70 3 3 0 0 0 0 0 0 0 0 
3 0 10 0 0 0 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 0 0 0 0 0 
6 0 0 0 0 0 0 0 0 0 0 0 0 
7 0 0 0 0 0 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 0 0 0 0 0 
24 0 0 0 0 0 0 0 0 0 0 0 0 
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Table 13: K. pneumoniae inocula of 25 % dextrose in at 25 
o
C and 35 
o
C 
The cfu/mL and the percentage survival at each time point are shown below. 
 
cfu/mL 1000 500 250 125 62 31 
Time:Hrs 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 
0.5 1000 1000 310 270 110 30 10 3 3 3 0 0 
1 610 430 165 20 0 0 0 0 0 0 0 0 
2 520 230 6 0 0 0 0 0 0 0 0 0 
3 40 70 0 0 0 0 0 0 0 0 0 0 
4 0 10 0 0 0 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 0 0 0 0 0 
6 0 0 0 0 0 0 0 0 0 0 0 0 
7 0 0 0 0 0 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 0 0 0 0 0 
24 0 0 0 0 0 0 0 0 0 0 0 0 
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Table 14:  K. pneumoniae inocula in12.5 % dextrose at 25 
o
C and 35 
o
C. 
The cfu/mL and the percentage survival at each time point are shown below 
 
cfu/mL 1000 500 250 125 62 31 
Time:Hrs 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 
0.5 950 940 460 410 210 230 0 0 0 0 0 0 
1 810 750 300 400 200 100 0 0 0 0 0 0 
2 540 470 340 390 173 100 0 0 0 0 0 0 
3 520 410 330 370 90 10 0 0 0 0 0 0 
4 560 440 290 360 43 13 0 0 0 0 0 0 
5 560 480 340 360 6 3 0 0 0 0 0 0 
6 430 380 280 330 0 0 0 0 0 0 0 0 
7 480 320 330 313 0 0 0 0 0 0 0 0 
8 300 360 240 160 0 0 0 0 0 0 0 0 
24 0 0 0 0 0 0 0 0 0 0 0 0 
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Table 15: K. pneumoniae inoculum in 10 % dextrose   at 25 
o
C and 35 
o
C  
The cfu/mL and the percentage survival at each time point are shown below. 
cfu/mL 1000 500 250 125 62 31 
Time:Hrs 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 
0.5 1000 1000 360 400 190 183 100 90 3 0 6 3 
1 680 990 340 370 150 116 30 60 0 0 0 0 
2 660 960 320 320 130 120 30 10 0 0 0 0 
3 640 930 300 320 120 90 6 3 0 0 0 0 
4 640 760 270 300 110 70 3 3 0 0 0 0 
5 590 680 260 260 100 66 3 10 0 0 0 0 
6 570 640 260 250 90 60 0 3 0 0 0 0 
7 590 620 200 200 100 50 3 10 0 0 0 0 
8 450 600 150 190 80 40 3 0 0 0 0 0 
24 430 500 180 90 60 20 0 0 0 0 0 0 
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Table 16:  K. pneumoniae inocula in 6 % dextrose at 25 
o
C and 35 
o
C  
The cfu/mL and the percentage survival at each time point are shown below. 
cfu/mL 1000 500 250 125 62 31 
Time:Hrs 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 
0.5 950 880 460 470 210 176 126 120 86 0 0 3 
1 980 800 380 450 200 146 123 100 10 0 0 0 
2 870 780 410 460 180 120 110 120 0 0 0 0 
3 880 900 446 490 230 160 130 140 0 0 0 0 
4 890 900 403 500 240 200 130 120 0 0 0 0 
5 910 940 490 530 230 210 130 130 0 0 0 0 
6 940 930 480 530 250 200 130 110 0 0 0 0 
7 980 930 600 650 280 230 120 120 0 0 0 0 
8 980 940 610 690 310 240 130 160 0 0 0 0 
24 1120 1200 636 820 360 223 140 170 0 0 0 0 
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Table 17: K. pneumoniae inocula in 3 % dextrose at 25 
o
C and 35 
o
C  
The cfu/mL and the percentage survival at each time point are shown below. 
 
cfu/mL 1000 500 250 125 62 31 
Time:Hrs 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 
0.5 980 980 360 390 210 180 120 120 70 40 0 0 
1 980 940 380 436 200 190 100 120 10 20 0 0 
2 970 950 410 430 190 210 150 110 3 3 0 0 
3 980 910 440 390 290 240 110 100 3 0 0 0 
4 990 930 400 390 240 250 110 100 0 0 0 0 
5 910 990 490 410 230 280 90 116 0 0 0 0 
6 940 980 480 450 250 270 130 110 0 0 0 0 
7 980 970 450 446 280 280 130 120 0 0 0 0 
8 980 980 410 500 300 310 126 130 0 0 0 0 
24 1240 1340 880 940 340 410 130 166 0 0 0 0 
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Table 18: K. pneumoniae inoculum in 2 % dextrose in at 25 
o
C and 35 
o
C  
The cfu/mL and the percentage survival at each time point are shown below. 
cfu/mL 1000 500 250 125 62 31 
Time:Hrs 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 25
o
C 35
o
C 
0.5 990 910 490 510 190 180 130 130 70 66 0 0 
1 910 980 486 546 290 153 126 90 36 20 0 0 
2 940 980 410 560 240 240 123 160 33 16 0 0 
3 980 970 400 580 230 103 110 130 23 10 0 0 
4 980 960 410 490 250 100 119 130 16 10 0 0 
5 960 980 500 600 180 100 123 140 3 6 0 0 
6 940 1010 496 680 150 180 126 150 0 0 0 0 
7 980 1200 460 690 110 186 120 160 0 0 0 0 
8 990 1180 490 600 130 180 120 150 0 0 0 0 
24 1330 1500 900 900 290 290 126 170 0 0 0 0 
 
